| Market Cap | 611.74M | P/E | 45.09 | EPS this Y | - | Ern Qtrly Grth | -4.00% |
| Income | 30.15M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 1.00% |
| Sales | 81.76M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -9.00% |
| Dividend | N/A | Price/Book | 4.32 | EPS next 5Y | - | 52W High Chg | -39.00% |
| Recommedations | - | Quick Ratio | 6.38 | Shares Outstanding | 50.13M | 52W Low Chg | 8.00% |
| Insider Own | 20.44% | ROA | 14.71% | Shares Float | 39.50M | Beta | 0.74 |
| Inst Own | 8.94% | ROE | 18.98% | Shares Shorted/Prior | -/- | Price | 12.18 |
| Gross Margin | 91.81% | Profit Margin | 36.88% | Avg. Volume | 443 | Target Price | - |
| Oper. Margin | 42.37% | Earnings Date | - | Volume | 27 | Change | 0.00% |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.